Statins and angiogenesis in non-cardiovascular diseases

Fatemeh Zahedipour; Alexandra E Butler; Manfredi Rizzo; Amirhossein Sahebkar

doi:10.1016/j.drudis.2022.07.005

Statins and angiogenesis in non-cardiovascular diseases

Drug Discov Today. 2022 Oct;27(10):103320. doi: 10.1016/j.drudis.2022.07.005. Epub 2022 Jul 16.

Authors

Fatemeh Zahedipour¹, Alexandra E Butler², Manfredi Rizzo³, Amirhossein Sahebkar⁴

Affiliations

¹ Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
² Research Department, Royal College of Surgeons in Ireland, Bahrain, Adliya, Bahrain.
³ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, 90133 Palermo, Italy.
⁴ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; School of Medicine, The University of Western Australia, Perth, Australia; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sahebkara@mums.ac.ir.

PMID: 35850434
DOI: 10.1016/j.drudis.2022.07.005

Abstract

Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.

Keywords: Angiogenesis; Bone disease; Brain disease; Cancer; Cardiovascular; Diabetes; Ocular disease; Preeclampsia; Statins; Vascularization.

Publication types

Review

MeSH terms

Cardiovascular Diseases* / drug therapy
Cholesterol
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Neoplasms* / drug therapy
Neovascularization, Pathologic / drug therapy

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol